Navigation Links
CeNeS Pharmaceuticals plc: Update on Successful Phase III results,announced on Lead Product M6G

Further analysis of Phase III trial data underlines M6G's benefit compared to morphine in the treatment of post-operative pain

CAMBRIDGE, England, 7th March 2007 - CeNeS Pharmaceuticals plc (AIM: CEN), the Cambridge based biopharmaceutical company today announces additional data from the pivotal Phase III trial (M6G022) of M6G (morphine-6-glucuronide) in over 500 patients with post-operative pain. The preliminary data released on 20th February showed that M6G provided equivalent pain relief to morphine but induced significantly less post-operative nausea and vomiting (PONV).

Secondary Data Results

The additional secondary data now received by CeNeS shows that:

* less anti-emetic drugs (drugs used to control nausea and vomiting) were required in patients treated with M6G compared with those on morphine; and * M6G exhibited a long duration of analgesic action.

This was the first Phase III study where patients were given a complete pain management programme with M6G (rapid titration to comfort followed by PCA for up to 48 hours) and the first Phase III trial where nausea and vomiting were assessed as primary endpoints.

Management of PONV/use of anti-emetics

In addition to the clear nausea and vomiting reductions of over 25% announced last week, secondary data reveals that patients receiving M6G required over 20% less anti-emetic medication over the 0-24 hour period than those in the morphine group. This shows that not only does M6G induce significantly less nausea and vomiting than morphine, but also that the post-operative anti-emetic treatment required is considerably reduced.

The potential for reduced anti-emetic drug costs combined with the reduction in medical assistance and the improved patient comfort due to lower PONV supports CeNeS justification of a substantial price premium for M6G compared to morphine.

Drug consumption

It has been sh
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Major New Review Supports the Broader Potential of CeNeS COMT Inhibitor Discovery Programme
2. Independent publication supports the profile of CeNeS phase II compound, CNS 5161
3. CeNeS Pharmaceuticals Plc Announces Preliminary Results for The Year Ending 31 December 2006
4. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
5. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
7. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
8. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
9. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
10. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
11. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
Post Your Comments:
(Date:9/4/2008)...wswire/ -- Southern Research Institute,today annou...has selected,the organization to participate in th...n Center Network (MLPCN). The MLPCN -- a collabora...Libraries Program which is,designed to benefit hum...an,genome and validate future targets for drug dis...
(Date:9/4/2008)...or Ipilimumab to be Presented, PRINCETON, N.J., S...sdaq: MEDX ) announced today that nine clinical a...TLA-4 antibody, in melanoma are scheduled to be,th... the European Society,for Medical Oncology (ESMO) ...y of the following abstracts will include updated ...
(Date:9/4/2008)...edule with Two Abstracts Accepted for Presenta...2008, BRIDGEWATER, N.J., Sept. 4 /- ...ceutical company focused on the treatment of,cardi...he appointment of,Peter L. Garrambone, Jr. to the ... career includes more than 50 pharmaceutical,trans...
(Date:9/3/2008)...wire-FirstCall/ -- Simcere,Pharmaceutical Group (N...f,branded generic pharmaceuticals and manufacturer...(also known as Endostar) in China,announced the i...At the request of the SFDA, Simcere initiated a Ph...ty and therapeutic efficacy of Endu, a modified,ve...
Breaking Medicine Technology:Southern Research Institute Wins $14.7 Million NIH Award to Participate in Molecular Libraries Probe Production Center Network 2Southern Research Institute Wins $14.7 Million NIH Award to Participate in Molecular Libraries Probe Production Center Network 3Southern Research Institute Wins $14.7 Million NIH Award to Participate in Molecular Libraries Probe Production Center Network 4Medarex Announces Presentations at the 33rd Congress of the European Society for Medical Oncology 2Medarex Announces Presentations at the 33rd Congress of the European Society for Medical Oncology 3Aegerion Pharmaceuticals, Inc. adds Peter Garrambone to Board of Directors, Secures Additional Capital for Clinical Trials 2Simcere Pharmaceutical Group Announces Interim Results of Endu Phase IV Clinical Study 2Simcere Pharmaceutical Group Announces Interim Results of Endu Phase IV Clinical Study 3Patients With Asthma and Seasonal Allergies Respond Better to Advair 28R 29 for Their Asthma Than Singulair 28TM 29 2107 1Patients With Asthma and Seasonal Allergies Respond Better to Advair 28R 29 for Their Asthma Than Singulair 28TM 29 2107 2Patients With Asthma and Seasonal Allergies Respond Better to Advair 28R 29 for Their Asthma Than Singulair 28TM 29 2107 3People with obstructive sleep apnea at risk for cardiac stress on airline flights 19674 1People with obstructive sleep apnea at risk for cardiac stress on airline flights 19674 2Body Positive Marks a New Era With Continued Commitment and a New Name 3A The Southwest Center for HIV AIDS 19672 1Body Positive Marks a New Era With Continued Commitment and a New Name 3A The Southwest Center for HIV AIDS 19672 2Body Positive Marks a New Era With Continued Commitment and a New Name 3A The Southwest Center for HIV AIDS 19672 3Sen Edward Kennedy Hospitalized After Seizure 19669 1Sen Edward Kennedy Hospitalized After Seizure 19669 2
...ignificantly,increases patients_ overall survival ...ublished,yesterday in the Journal of Clinical Onco...) was shown to significantly improve,survival in p...chemotherapy alone.1 Follicular lymphoma is the mo...ssing but incurable form of,lymphoma. , The study ...
...ed with,Exforge achieved recommended blood pressur...Hg in,systolic blood pressure observed in patients... monotherapy[1] , Nearly 70% of those with high b...d most require two or more,medications to achieve ... - Exforge®,a single-tablet combination of tw...
Other Medicine Technology:Innovative Cancer Drug MabThera Again Shown To Improve Survival,Rates In Patients With Lymphoma 2Innovative Cancer Drug MabThera Again Shown To Improve Survival,Rates In Patients With Lymphoma 3Innovative Cancer Drug MabThera Again Shown To Improve Survival,Rates In Patients With Lymphoma 4Exforge Helps Vast Majority of Patients Effectively Control Their,Blood Pressure After Failing on Other Medicines, According to New,Clinical Data 2Exforge Helps Vast Majority of Patients Effectively Control Their,Blood Pressure After Failing on Other Medicines, According to New,Clinical Data 3Exforge Helps Vast Majority of Patients Effectively Control Their,Blood Pressure After Failing on Other Medicines, According to New,Clinical Data 4Exforge Helps Vast Majority of Patients Effectively Control Their,Blood Pressure After Failing on Other Medicines, According to New,Clinical Data 5Exforge Helps Vast Majority of Patients Effectively Control Their,Blood Pressure After Failing on Other Medicines, According to New,Clinical Data 6Exforge Helps Vast Majority of Patients Effectively Control Their,Blood Pressure After Failing on Other Medicines, According to New,Clinical Data 7Exforge Helps Vast Majority of Patients Effectively Control Their,Blood Pressure After Failing on Other Medicines, According to New,Clinical Data 8
(Date:9/4/2008).... Free drug samples provided to physicians by pha...insured patients more in the long run, according t...rsity Baptist Medical Center and colleagues. , T...abits of more than 70 physicians in a university-a... immediately before and after the closing of their...
(Date:9/4/2008)...n a case-control study, the presence of measles vi... and GI disturbances than in children with only GI... onset were unrelated to MMR vaccine timing. Stud...ary of Science on September 4 ( http://dx.plos.or... implementation of measles vaccines in 1963, three...
(Date:9/4/2008)...ence of instructions they say could help doctors e...lthDay News) -- Vaccine safety experts say that al...eive vaccinations with close monitoring and a set ...ptember issue of Pediatrics , a team of experts l...h a step-by-step set of instructions -- an algorit...
(Date:9/4/2008)...ger labeling about fungal infection risk , ...l health authorities have asked the manufacturers ...ster safety warnings on the risk of developing opp...ra, Cimzia, Enbrel and Remicade, belong to a class...ha blockers (TNF-alpha blockers), which suppress t...
Breaking Medicine News(10 mins):Health News:Free drug samples may end up costing uninsured more 2Health News:Free drug samples may end up costing uninsured more 3Health News:Study firmly shows no connection between measles, mumps, rubella (MMR) vaccine and autism 2Health News:Study firmly shows no connection between measles, mumps, rubella (MMR) vaccine and autism 3Health News:Even Kids With Known Allergies Can Be Safely Vaccinated 2Health News:FDA Demands Tougher Warnings on Immunosuppressive Drugs 2Health News:FDA Demands Tougher Warnings on Immunosuppressive Drugs 3
...olocaust are more likely to suffer from cancer and...d his colleagues at Israel's //Haifa University su...ear-starvation of European Jews during World War I...at the incidence and death rate from cancer in aro...
... of Goan’s can be the main cause for HIV/AIDS spre...ollow the Government policies // and initiatives t...Many labourers who got jobs in Goa, since it has b...ing with them the dreadful virus (HIV) when they a...
...er gave Isabelle Taylor, of St Annes, Lancs, a mob... grand child would end up constantly // sending te...loping a condition known as ‘repetitive strain in...n in Britain to suffer from this condition. Her m...
... researchers plan to ask women to donate their egg... cells matched to patients // which they say would...ng diseases such as diabates or neurodegenerative ...nic stem (ES) cells after creating human embryos c...
Other Medicine News:
VascoScrew is a low profile unipolar pacing lead with a fixed screw for permanent pacing. Due to latest technologies, VascoScrew 6/60 M is compatible to all pacemaker-cavities with the size of IS-1 (
The VascoTip J 9/60 PU is a unipolar tined, J-preformed permanent pacing lead. Due to advanced technology, VascoTip J 9/60 PU M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm),
The VascoTip J 9/60 PU is a unipolar tined, J-preformed permanent pacing lead. Due to advanced technology, VascoTip J 9/60 PU M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm),
The Guidant Fineline EZ leads with protective capsule are bipolar endocardial and designed for permanent implantation with pulse generators for cardiac pacing.
Medicine Products: